5 Questions to Ask Before Any Practice Investment

Every January, my inbox fills with vendor emails promising the “must-have” technology that will “transform” my practice. Advanced OCT modules. AI diagnostic platforms. Practice management upgrades. Myopia management systems.

The pressure to keep up is real. But in a rural Oklahoma practice where every dollar matters, I’ve learned that the right question isn’t “What’s new?” It’s “What moves the needle?”

Over the past five years, I’ve made both brilliant investments (a YAG laser that generates $35,000 annually) and regrettable ones (a social media management service that produced zero measurable results). The difference wasn’t the technology itself—it was the framework I used to evaluate each opportunity.

Here are the five questions that now guide every investment decision in my practice. They’ve saved me from expensive mistakes and helped me identify opportunities I might have otherwise overlooked.

INVESTMENT QUESTION 1: DOES THIS SOLVE A PATIENT ACCESS PROBLEM?

The Test: If a patient currently has to travel, wait or go without care, you’ve identified a genuine access gap. These investments deliver both clinical and financial returns.

My Example: Before purchasing a YAG laser, I referred 15-20 patients monthly for posterior capsulotomies and laser peripheral iridotomies. Each patient faced a three-hour round-trip drive to reach the nearest ophthalmologist. Many delayed treatment due to transportation barriers.

The YAG laser solved a real access problem. It wasn’t about competing with other optometrists—it was about eliminating unnecessary patient burden.

Investment: $45,000 (refurbished unit)
Break-even: 18 months
Annual revenue: $35,000
Patient impact: 180+ patients annually avoid unnecessary travel

The access principle applies beyond expensive equipment. When I upgraded to a cloud-based EHR with a patient portal, I solved another access problem: patients couldn’t schedule appointments, request refills or access records outside business hours. The portal reduced phone calls by 40% and dropped no-shows by 30%.

Red Flag: If the investment doesn’t solve an existing patient problem, it’s likely a “nice-to-have” rather than a “must-have.” Nice-to-haves rarely generate ROI that justifies their cost.

2026 Application: With scope expansion accelerating nationwide, ask yourself: Are my patients traveling for procedures I could perform? Are they going without care because specialists are inaccessible? Those gaps represent both clinical opportunities and revenue potential.

INVESTMENT QUESTION 2: WHAT’S THE REALISTIC ROI TIMELINE?

The Test: Calculate break-even based on conservative projections, not vendor promises. If you can’t recoup your investment within 24-36 months, the risk probably outweighs the reward.

My Example: When evaluating an advanced OCT upgrade, the vendor projected I’d perform 150-180 scans monthly, generating $90,000+ annually. Reality check: my patient volume couldn’t support that number.

My conservative calculation:

• Current OCT scans: 110 per month
• Projected increase with anterior segment capability: 20 additional scans monthly
• New monthly scans: 130
• Revenue per scan: $47 (average Medicare reimbursement for CPT 92134)
• Additional monthly revenue: $940
• Additional annual revenue: $11,280

Investment: $65,000 (refurbished Zeiss Cirrus)
Financing: 5-year loan at $1,200/month
True break-even: 14 months (considering both direct revenue and higher-level exam billing)

The vendor’s projection would have suggested 8-month break-even. My realistic projection showed 14 months—still excellent, but honest.

The ROI formula that works:

Monthly Revenue = (Expected Patient Volume) × (Revenue Per Service) × (Realistic Adoption Rate)

Most practices overestimate all three variables. Cut vendor projections by 30% to get realistic numbers.

Red Flag: If break-even extends beyond 36 months, you’re either overestimating revenue or underestimating the true cost of ownership (maintenance, staff time, software subscriptions).

2026 Application: AI retinal screening platforms now promise $30,000-50,000 in annual revenue. Run the numbers: How many patients will actually opt in? What’s your realistic reimbursement rate? Does your payer mix support the coding? Conservative projections prevent expensive disappointments.

INVESTMENT QUESTION 3: WILL THIS DIFFERENTIATE ME OR JUST CATCH ME UP?

The Test: Differentiation creates competitive advantage. Catch-up investments prevent competitive disadvantage. Both matter, but they generate value differently.

Differentiation investments attract new patients and command premium pricing. Examples:

• Scope expansion procedures (laser capsulotomies, injections)
• Oculomics/AI cardiovascular screening
• Specialty contact lens fitting (scleral lenses, ortho-k)

These position you as a specialist or advanced provider. Patients travel TO your practice for these services.

Catch-up investments prevent patient loss but rarely attract new ones. Examples:

• Digital refraction systems (when all competitors have them)
• Online appointment scheduling (now baseline expectation)
• Modern frame displays (hygiene stakes matter post-COVID)

These are necessary but not differentiating. You invest to stay competitive, not to leapfrog competitors.

My Example: When I added AI retinal screening (RetInSight platform integrated with our OCT), it was differentiation. No other practice within 90 miles offered cardiovascular risk assessment during eye exams. We market it explicitly: “Your eye exam can detect heart disease risk.”

Result: Three patients specifically scheduled appointments because they saw our AI screening promotion on social media. All three were new to the practice, and all three referred family members.

Contrast this with upgrading our frame displays. Post-COVID, patients expected touchless browsing and sanitized frames. Our old open displays felt outdated. The investment ($8,500) was necessary to prevent patient loss—but it didn’t attract new patients.

Red Flag: If every competitor already offers the technology, you’re playing catch-up, not differentiating. These investments are often necessary, but don’t expect dramatic revenue growth.

2026 Application: Myopia management is transitioning from differentiation to catch-up. In 2020, offering ortho-k positioned you as cutting-edge. In 2026, parents expect it. Evaluate accordingly: Are you investing to lead or to avoid falling behind?

INVESTMENT QUESTION 4: CAN I AFFORD NOT TO DO THIS?

The Test: Some investments aren’t about growth—they’re about survival. These are often operational upgrades that prevent catastrophic problems: security breaches, regulatory non-compliance, or total workflow failures.

My Example: Our legacy practice management software was 12 years old. It worked—barely. But it lacked cloud backup, had no patient portal, required constant IT support, and didn’t integrate with our EHR. I resisted upgrading for two years because it wasn’t “broken.”

Then our server crashed. We lost three days of scheduling data. The recovery cost $2,400, and we couldn’t reach patients to confirm appointments.

That crisis forced the decision I should have made earlier: upgrade to a modern, cloud-based system.

Investment: $15,000 setup + $800/month subscription
Break-even: 8 months (from reduced IT costs, improved billing efficiency, and eliminated no-shows)
Real value: Risk mitigation—we’ll never lose data to hardware failure again

The “can’t afford NOT to” investments include:

• Cybersecurity upgrades (HIPAA compliance, ransomware protection)
• Cloud-based backups (hardware failure happens)
• Staff training (untrained staff create liability and inefficiency)
• Regulatory compliance (scope expansion requires malpractice insurance updates, continuing education)

Red Flag: If you’re delaying an investment because “things are working fine,” ask yourself: What happens if this fails? If the answer is “disaster,” you can’t afford to wait.

2026 Application: With AI proliferating, data privacy becomes critical. Are your systems HIPAA-compliant when uploading images to cloud-based AI platforms? Can you document patient consent for AI analysis? These aren’t optional—they’re risk management.

INVESTMENT QUESTION 5: DOES THIS ALIGN WITH MY 3-YEAR VISION?

The Test: Every investment should move you toward a long-term practice identity. If it doesn’t fit your strategic direction, it’s a distraction—even if it’s profitable.

My Example: In 2022, a colleague urged me to invest in a dry eye specialty clinic. The business case was solid: high patient demand, good reimbursement, premium product sales. But my 3-year vision focused on scope expansion and medical optometry (lasers, injections, advanced disease management).

A dry eye clinic would require staff training, new equipment and significant time—pulling resources away from my strategic priorities. I passed.

Was it profitable? Probably. Was it right for my practice vision? No.

Contrast this with my YAG laser investment. It aligned perfectly: I wanted to position my practice as a comprehensive medical optometry hub serving rural patients. Laser procedures fit that vision seamlessly.

The 3-year vision framework:

Strategic priorities:

1. What type of practice do you want to be? (Primary care? Specialty? Medical? Optical retail?)
2. What patient population do you serve best?
3. What’s your geographic/competitive position?

Investment alignment test:

• Does this investment strengthen your strategic identity?
• Does it serve your target patient population?
• Does it reinforce your competitive advantages?

If the answer to all three is “yes,” invest. If you answer “no” to even one, reconsider—even if ROI looks attractive.

Red Flag: “Shiny object syndrome”—investing in every new opportunity without strategic coherence—leads to a scattered practice identity. Patients won’t know what you’re known for, and you’ll burn out trying to excel at everything.

2026 Application: The optometry landscape is expanding rapidly. You could pursue myopia management, oculomics, aesthetic procedures, specialty contact lenses or advanced surgical co-management. You cannot do all of them well. Choose the investments that reinforce your 3-year vision, not the ones that simply promise revenue.

PUTTING IT ALL TOGETHER: A REAL DECISION

In December 2025, I evaluated whether to add scleral lens fitting to my practice. Here’s how I applied the five questions:

1. Does it solve a patient access problem?
Yes. I refer eight to 10 keratoconus and irregular cornea patients annually to a specialist two hours away.

2. What’s the realistic ROI?

• Training cost: $2,500 (course + certification)
• Diagnostic set: $8,000
• Trial lens inventory: $6,000
• Total investment: $16,500
• Realistic patients per year: 12-15
• Revenue per fit: $800-1,200
• Annual revenue: $9,600-18,000
• Break-even: 14-20 months

3. Will this differentiate or catch up?
Differentiate. Only one practice within 60 miles fits sclerals.

4. Can I afford NOT to do this?
No immediate risk—this is a growth opportunity, not a survival necessity.

5. Does it align with my 3-year vision?
Yes. Medical/specialty optometry fits my strategic direction perfectly.

Decision: Move forward. All five questions pointed toward “yes.” Training scheduled for February 2026.

THE 2026 INVESTMENT LANDSCAPE

As independent optometry faces increasing competition from private equity-backed chains and online retailers, strategic investment becomes survival. But “strategic” doesn’t mean “expensive”—it means intentional. The practices that thrive in 2026 pick the right technology thoughtfully, aligned with patient needs and practice vision.

Because in independent optometry, every investment is a bet on your future. Make sure you’re betting wisely.

Read more on customer services here.